prostate cancer
Conditions
Interventions
A:New endocrine therapy followed by chemotherapy
B:Chemotherapy followed by new endocrine therapy
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Male; 2. Aged 18 to 80 years; 3. Histologically or cytologically confirmed adenocarcinoma of prostate; 4. Confirmed metastatic disease by conventional imaging and Diagnosed as metastatic castration-resistant prostate cancer according to the EAU guideline (2020 verision); 5. Not receiving the same new hormone therapy; 6. ECOG 0 - 2; 7. Estimated life expectancy >1 years; 7. Willing and able to provide informed consent; 8. Treatment and follow-up could be arranged.
Exclusion criteria
Exclusion criteria: 1. Previous treatment to primary lesion of prostate and metastatic lesions including radical prostatectomy, radical radiotherapy and radiotherapy of metastatic sites; 2. History of another cancer (except for basal cell carcinoma or other cancers cured for over 5 years); 3. Other severe disease, such as unstable heart disease, myocardial infarction within 6 months before enrollment, NYHA 3-4, uncontrolled hypertension after treatment, severe neural or mental disorder, uncontrolled active infection, acute gastric ulcer, hypercalcemia and COPD requiring hospitalization; 4. Enrolled in another trial before; 5. Not suitable for enrollment accouding to the researchers view.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| overall survival;PSA progression free survival; | — |
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Countries
China
Contacts
Public ContactDingwei Ye
Fudan University Shanghai Cancer Center
Outcome results
None listed